Back

The Gwangju Alzheimer's & Related Dementias (GARD) Cohort: Over a Decade of Korea's Largest Longitudinal Multimodal Study

Choi, K. Y.; Kang, S.; Cook, S.; Li, D.; Choi, Y. Y.; Seo, E. H.; Han, X.; Park, J. E.; Lee, S.; Lee, S.; Chung, J. Y.; Chong, A.; Choi, S.-M.; Ha, J.-M.; Song, M. K.; Lee, J. S.; Choo, I. H.; Kim, B. C.; Kim, H.; Farrer, L. A.; Gim, J.; Jun, G. R.; Lee, K. H.

2025-08-24 epidemiology
10.1101/2025.08.21.25333554 medRxiv
Show abstract

INTRODUCTIONAlzheimers disease (AD) is a major public health concern in Korea, with a high prevalence among older adults. A community-based longitudinal study is essential for tracking disease progression, identifying biomarkers, and developing targeted prevention and treatment strategies. The Gwangju Alzheimers and Related Dementias (GARD) cohort was established to address these needs through a multimodal approach. METHODSParticipants aged [≥]60 undergo comprehensive clinical evaluations, neuroimaging, and biospecimen collection for multi-omics analyses (genomics, transcriptomics, proteomics, microbiome) at baseline and systematic follow-up visits. RESULTSFrom over 17,000 screened individuals, 12,877 were enrolled. Baseline diagnoses include 5,995 cognitively unimpaired (CU), 4,025 mild cognitive impairment (MCI), and 1,026 AD dementia. The resource includes MRI scans (n=10,843) and extensive multi-omics data: genomic (n=10,775), proteome (n=116), and microbiome (n=595). DISCUSSIONThe integrated GARD dataset provides a powerful and scalable resource for identifying novel biomarkers, understanding disease heterogeneity, and advancing precision medicine for AD.

Matching journals

The top 2 journals account for 50% of the predicted probability mass.

50% of probability mass above